New York Wants to Ban Sugary Drinks from Food Stamp Purchases

Mayor Michael Bloomberg sought permission from the federal government to bar New York City%u2019s 1.7 million food stamp recipients from using them to buy sugary drinks such as sodas. Bloomberg, a staunch advocate of anti-obesity measures, sent the request to the United States Department of Agriculture, The New York Times reported.

FDA Panel Votes Against Arena's Diet Drug

Another diet drug, Arena Pharmaceuticals's Iorcaserin, appears to be in danger after a U.S. Food and Drug Administration advisory panel voted to reject it Thursday.

Daily Blogwatch: Are All Hedge Funds Scams?

Among Tuesday's top stories for investors: How do dividend-paying stocks stack up against non-dividend-paying stocks? Is Facebook making it easier for stalkers? Are all hedge funds scams?

Orexigen Shares Soar on Partnership Deal With Takeda

Orexigen jumped over 25% in premarket trading after announcing an exclusive partnership agreement potentially worth over $1 billion with Japan's Takeda Pharmaceutical to develop and commercialize Contrave, Orexigen's promising obesity drug.

'Fructose-Slurping' Cancer Could Sour the Soda Business

Soda and processed-food makers insist that all sugars are the same. Yet with studies linking high fructose corn syrup to obesity, diabetes and, most recently, pancreatic cancer, big brands are quietly backing away from using the corn-based sweetener.

Krispy Kreme doughnut burgers?

Is anyone concerned about America's obesity epidemic? Clearly, not the Hoosier family, who have invented the obviously titled "Krispy Kreme...

Vivus Hammered After FDA Panel's 'No' Vote

Pharmaceutical company Vivus is getting hammered in premarket trading, sinking more than 50% to around $5.32 in the wake of Thursday's vote by an FDA advisory panel against approving its weight-loss drug, Qnexa, based on safety concerns.

FDA Panel Rejects Weight-Loss Drug Qnexa

Pharmaceutical company Vivus and investors waited anxiously Thursday for the vote of an FDA advisory panel on the weight-loss drug Qnexa. The verdict is in, and by a vote of 9 to 7, panelists didn't support approving the drug as an obesity treatment.

Weight-Loss-Drug Maker Vivus Soars on FDA Review

An expert panel will review Vivus' potential blockbuster drug Qnexa on Thursday, with the FDA making a decision in October. The FDA acknowledges the drug's effectiveness in cutting weight, but it will certainly draw scrutiny over its side effects.

Four Trends That Will Dramatically Change China

The financial media's coverage of China tends to focus on trade-related topics, but China is undergoing deep cultural shifts that will dramatically alter its economic landscape. These four long-term trends could drastically change China -- and its relationship with the world.

McDonald's Shrek Glasses Add to Fast Food's Woes

McDonald's recall of tainted Shrek glasses is an unusual reminder of the downsides to America's love affair with the Golden Arches. And as McDonald's fights to avoid blame for a share of the obesity epidemic, the last thing it wants is more scrutiny of how it markets fast food to kids.

Would Soda Taxes Mean Flat Beverage Stocks?

Beverage company stocks may remain a sweet investment even if recently proposed taxes on soda are enacted. Companies such as Coca-Cola and PepsiCo have been diversifying into healthier product lines, which should help reduce the impact of soda taxes on their bottom lines.

Study Says Junk Food as Addictive as Heroin or Cigarettes

Is junk food as addictive as heroin or cigarettes? Previous studies have shown similarities between drug abusers and compulsive eaters, but a new study published Sunday in Nature Neuroscience provides evidence that those who are addicted to junk food experience similar cravings as drug addicts, require increasingly larger amounts of food to feel good and even have a harder time quitting.

Do Ads With Heavier Models Take a Heavy Toll on Profits?

The push to show "real" women in advertising seemed like a victory for womankind. But new research from Arizona State University suggests that all of those ads and magazines featuring everyday women can sometimes backfire -- and, in some cases, even make women feel worse.